RVL Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
RVL Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-21,348,648.6%
Buyback Yield
| Total Shareholder Yield | -21,348,648.6% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 16
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts
May 13RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares
May 12RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt
Apr 20Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?
Jan 05RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M
Oct 18RVL Pharmaceuticals: Chapter 2 - A Developing Quandary
Sep 22RVL Pharma in pact with Revision Skincare to broaden access to products
Aug 30GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M
Aug 11RVL Pharma posts preliminary 42% sales growth for eye treatment
Jul 07RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt
Jul 04RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture
Jun 15New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)
Apr 01RVL Pharmaceuticals: A Makeover For An Ugly Duckling
Mar 30Osmotica: A Different Breed Of Cat
Dec 14Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt
Aug 20Osmotica: Paring Down, Focusing On UPNEEQ
Jul 16Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RVLP.Q's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RVLP.Q's dividend payments have been increasing.
Dividend Yield vs Market
| RVL Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RVLP.Q) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (RVLP.Q) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate RVLP.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RVLP.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RVLP.Q's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RVLP.Q has not reported any payouts.